Ideaya Biosciences, Inc. (IDYA) intrinsic value & 10-year financials
Ideaya Biosciences, Inc. (IDYA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 62.1% a year to $218.7M, with an average return on invested capital of -1.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $32.85
- Market cap
- $2.9B
- Revenue (FY2025)
- $218.7M
- Revenue growth (10-yr CAGR)
- 62.1%
- ROIC (10-yr avg)
- -1.8%
- Free cash flow (FY2025)
- -$73.5M
IDYA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $218.7M | -$113.7M | -$1.28 | -$73.5M | -72.8% | -16.5% |
| FY2024 | $7.0M | -$274.5M | -$3.36 | -$251.4M | -4671.1% | -44.8% |
| FY2023 | $23.4M | -$113.0M | -$1.96 | -$117.6M | -574.9% | -36.0% |
| FY2022 | $50.9M | -$58.7M | -$1.42 | -$90.6M | -122.7% | -25.2% |
| FY2021 | $27.9M | -$49.8M | -$1.41 | -$58.4M | -179.9% | -29.2% |
| FY2020 | $19.5M | -$34.5M | -$1.40 | $55.0M | -180.9% | -34.8% |
| FY2019 | $0 | -$42.0M | — | -$40.7M | — | -61.5% |
| FY2018 | — | -$34.3M | — | -$29.3M | — | 112.6% |
| FY2017 | — | -$11.9M | — | -$14.0M | — | 119.4% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
IDEAYA Biosciences, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
IDEAYA Biosciences, Inc. has historically struggled to out-earn its cost of capital, averaging just -35.4% ROIC.
IDEAYA Biosciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, IDEAYA Biosciences, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-42.52 per share.